












Overview of  chronic hepatitis C
Review the evolution of  treatment options
Discuss current approved hepatitis C treatment 
Clinical Scenario
60 y/o Caucasian woman
Cirrhosis secondary to chronic hepatitis C  
Genotype 1a, treatment naïve 
Liver transplant    - March 2013 
Progressive cholestasis  - GGT 500 - 700
Liver biopsy           mild inflammation no fibrosis
Clinical Scenario
60-year-old woman , s/p  LT  in March 2013
No rejection, progressively elevated liver enzymes
Admitted in December 2013 
Worsening jaundice ( bilirubin of  8 mg/dl), 
hepatic encephalopathy, acute kidney injury 
(GFR of  8ml/min, requiring hemodialysis), 




1-2% US population infected:  3 - 4 million
More prevalent than HIV
Men >Women -Patients not aware of infection






























Goals of  Hepatitis C Treatment
Eradicate hepatitis C virus ( predicted by SVR )
Prevent complications of  liver disease
Delay disease progression
Prevent recurrence after liver transplant
Ghany, MG, Strader, DB, Thomas, DL, Seeff, LB. Diagnosis, management, and treatment of  hepatitis C: 
an update. Hepatology 2009; 49:1335. 





 NS5B nucleotide polymerase inhibitor
 Favorable administration profile
 Once daily, no food effect
 No drug-drug interactions

 NS3/4A protease inhibitor 
 Antiviral activity against GT 1, 2, 4, 5 and 6
 One capsule, once per day
Simeprevir (TMC 435)
































Sofosbuvir + Simeprevir ± RBV
COSMOS Cohort 2- Gen 1, Naive and NR, F3-F4




























N=80 N=27 N=14 N=24









– Once-daily, oral, 90-mg 
NS5A inhibitor
 Sofosbuvir
‒ Once-daily, oral, 400-mg 
NS5B inhibitor
 Sofosbuvir/Ledipasvir (HARVONI)
– Once-daily, oral, fixed-dose 
(90/400 mg) combination tablet




Daclatasvir + Sofosbuvir 
ALLY-2 Trial: Results for Genotype 2
SVR12, Genotype 2
Wyles DL, et al. N Engl J Med. 2015;373:714-25.
Abbreviations: DCV = daclatasvir; SOF = sofosbuvir
11/11 5/6 2/2
MK-5172  +  MK- 8742
5 
SVR 12: Full Analysis Set 
Non-virologic failure 4 3 1 0 0 
Breakthrough 1 1 0 0 0 
Relapse 12 9 1 0 2 
Zeuzem et al., Abstract #G07, EASL 2015 















































































Genotype 1,4 decompensated cirrhosis



















 Source: Flamm SL, al. 65th AASLD. 2014: Abstract 239.
DCV + SOF + RBV in Decompensated Cirrhosis 
ALLY-1: Results for Advanced Cirrhosis Cohort
ALLY-1: SVR12 Results for Advanced Cirrhosis Cohort by Child-Pugh Class









Watt  K, Veldt  B, Charlton M A Practical Guide to the Management of  HCV Infection Following Liver 
Transplantation.  American Journal of  Transplantation 2009; 9: 1707–1713
Sofosbuvir/Ledipasvir + RBV













N=56 N=26 N=25 N=3
CPT A
LDV/SOF + RBV 12 Weeks LDV/SOF + RBV 24 Weeks
N=5
CPT C
 Source: Reddy KR, al. 65th AASLD. 2014: Abstract 8.
MK-5172  +  MK- 8742
14 
SVR12: GZR/EBR for 12 Weeks in GT1  
Patients With Chronic Kidney Disease  
• GZR/EBR was generally safe and well tolerated. 
aNoncirrhotic, interferon-intolerant patient with HCV GT1b infection relapsed at FW12.  
bLost to follow-up (n = 2), n = 1 each for death, noncompliance, withdrawal by subject, and withdrawal by physician 
(owing to violent behavior). 












Modified Full Analysis Set 
16 Weeks 















 Source: Osinusi A, et al. 65th AASLD. 2014: Abstract 84.
HIV+HCV Coinfection
NIAID ERADICATE Trial  - Sofosbuvir-Ledipasvir in GT1 





Week 4 100 (n =13) 100 (n=37)
Week 8 100 (n =13) 100 (n=37)
Week 12 (EOT) 100 (n =13) 100 (n=37)
SVR 4 100 (n =13) 97 (n=36)
SVR 8 100 (n =13) 97 (n=36)
SVR 12 100 (n =13) 97 (n=36)
Our experience  - UIHC LIVER CENTER
Sofosbuvir + Simeprevir
37 patients - HCV recurrence post-transplant
31 geno 1 - sofosbuvir 400 mg +simeprevir 150 mg 
3 geno 2 sofosbuvir 400 mg and ribavirin 400 mg 
3 geno 3 sofosbuvir 400 mg and ribavirin 400 mg
Our experience  - UIHC LIVER CENTER
12/37 patients - cirrhosis post-transplant
Immunosupression – calcineurin  inhibitor
32/37 patients – HCV treatment experienced 
Our experience - UIHC Liver Center 
Sofosbuvir + Simeprevir      for post LT HCV 
34 patients – achieved SVR  12
3 genotype 1 - relapsers  (all cirrhotic)
Well tolerated
No dose changes on immunosuppression
No rejection
BACK  TO 
OUR  PATIENT
Clinical Scenario
Post LT patient with fibrosing cholestatic hepatitis C.
Liver failure, renal failure, respiratory failure.  
Serum HCV-RNA level was 7.95 log IU/mL.  
In view of  her life threatening condition  
IRB approval - compassionate use of  hep C treatment 
Clinical Scenario
Combination of  sofosbuvir and ribavirin 
Reduced doses due to severe renal impairment
Sofosbuvir - 100 mg daily based on pharmacokinetics 
Dose increased to 200 mg after 1 week
Full dose sofosbuvir(400 mg daily)  after 2 weeks
Clinical Scenario
Ribavirin started at 200 mg once a week
Increased to 200 mg daily 2 weeks later
As renal function improved, ribavirin to 400mg daily 
and 800 mg daily (after 4 weeks). 
HCV RNA viral load decreased > 1 log at 2 weeks 
HCV RNA viral load undetectable at 12 weeks
Clinical Scenario
Kidney function improved, normal baseline at 8 weeks 
Liver chemistry tests normalized after 8 weeks. 
Patient was discharged to rehab after 4 weeks 
Complete resolution of  her multi-organ dysfunction 
Patient completed 24 weeks of  therapy 
Achieved sustained virologic response
The Good  !!!
Therapeutic  options   - Hepatitis C treatment in 2016
Therapeutic  options   - Hepatitis C treatment in 2016

The Bad  !
Drug Interactions - Sofosbuvir & Amiodarone
Viekira Pak -Risk of Liver Failure in Cirrhosis
FDA Adverse Event Reporting System (FAERS) 
Viekira Pak - 26 cases of  hepatic decompensation and 
liver failure in patients with underlying cirrhosis. 
Some events resulted in liver transplantation or death. 




New generation DAA – IFN-free combination
Rapid evolution – new therapies   SVR  > 95 %    
Expand pool of  tx candidates (cirrhosis, ESRD)
Referrals  - potential to erradicate hepatitis C
Updates       - www.hcvguidelines.org

